BRCA胚系突变携带者的子宫内膜癌风险:系统综述与荟萃分析
该系统综述与荟萃分析纳入11项研究、共13 871例BRCA1/2胚系突变携带者,评估子宫内膜癌(EC)及子宫乳头状浆液性癌(UPSC)风险。BRCA1/2携带者EC合并患病率为0.59%(82/13 827),UPSC为0.16%(19/11 582);BRCA1与BRCA2携带者EC相对风险1.18(95%CI 0.7-2.0)。作者认为多数研究提示EC风险轻度增加(主要为BRCA1),是否同期行子宫切除应个体化决策。
要点
- BRCA1/2携带者EC合并患病率0.59%,UPSC为0.16%。
- BRCA1 vs BRCA2的EC相对风险1.18(95%CI 0.7-2.0)。
- 是否同期子宫切除应结合年龄、突变类型等个体化决定。
核心结论
- 多数纳入研究提示BRCA突变携带者子宫内膜癌风险轻度增加,主要见于BRCA1携带者。
- 是否在降低风险输卵管卵巢切除(RRSO)时同期行预防性子宫切除应个体化决策。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Cochrane Central Register of Controlled Trials、BIOSIS、Medline(Ovid)、Web of Science、ClinicalTrials.gov及Google Scholar。
- 纳入评估BRCA1/2胚系突变携带者EC及UPSC风险的随机对照研究、队列研究和病例对照研究,最终纳入11项研究。
- 采用OpenMetaAnalyst 2012软件分析,以Newcastle-Ottawa量表评估方法学质量,采用Mantel-Haenszel统计方法。
主要发现
- 共识别13 871例BRCA1和BRCA2突变携带者。
- BRCA1/2携带者EC合并患病率为82/13 827(0.59%),UPSC为19/11 582(0.16%)。
- BRCA1携带者EC患病率46/7429(0.62%),BRCA2携带者17/3546(0.47%),相对风险1.18(95%CI 0.7-2.0)。
- BRCA1携带者UPSC患病率15/7429(0.2%),BRCA2携带者3/3546(0.08%),相对风险1.39(95%CI 0.5-3.7)。
临床怎么用
- 对BRCA突变携带者评估EC风险时应考虑突变类型,BRCA1携带者风险相对更明显。
- RRSO时是否同期行预防性子宫切除需结合患者年龄、突变类型、未来激素替代治疗需求、乳腺癌病史、他莫昔芬使用及个人手术风险个体化决定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) is standard treatment among women with BRCA mutations. The aim of this meta-analysis is to evaluate the risk of endometrial cancer (EC) in BRCA1 or BRCA2 germline mutation carriers and to examine the justifiability of prophylactic hysterectomy at the time of RRSO. DATA SOURCES: PubMed, Cochrane Central Register of Controlled Trials, BIOSIS, Medline (Ovid), Web of Science, ClinicalTrials.gov, and Google Scholar were searched. Eleven articles were selected and analyzed using the OpenMetaAnalyst 2012 software. METHODS OF STUDY SELECTION: Randomized controlled studies, cohort studies, and case-control studies evaluating the risk of EC and specifically uterine papillary serous carcinoma (UPSC) in germline BRCA1/2 mutation carriers were included. Articles were excluded if they did not meet the inclusion criteria, or if data were not reported and the authors did not respond to inquiries. We assessed the methodological quality of the included studies on the basis of the Newcastle-Ottawa scale. Dichotomous results from each of the studies eligible for the meta-analysis were expressed as the proportion of patients with EC or UPSC per total number of BRCA mutation carriers, with 95% confidence interval (CI). The Mantel-Haenszel statistical method was used. TABULATION, INTEGRATION, AND RESULTS: Eleven studies reported the outcome of interest and were included in the final meta-analysis. In total, 13 871 carriers of BRCA1 and BRCA2 mutations were identified. The pooled prevalence rates of EC and UPSC in BRCA1/2 mutation carriers were 82/13 827 (0.59%) and 19/11 582 (0.16%), respectively. The EC prevalence was 46/7429 (0.62%) in BRCA1 mutation carriers and 17/3546 (0.47%) in BRCA2 mutation carriers, with relative risk of 1.18 (95% CI, 0.7-2.0). For UPSC, the prevalence was 15/7429 (0.2%) and 3/3546 (0.08%) among BRCA1 and BRCA2 mutation carriers, respectively, (relative risk 1.39; 95% CI, 0.5-3.7). CONCLUSION: Most studies in this meta-analysis suggest a slightly increased risk of EC in BRCA mutation carriers, mainly for BRCA1. The decision regarding concurrent hysterectomy should be tailored individually to each patient on the basis of the patient's age, type of mutation, future need for hormone replacement treatment, history of breast cancer, tamoxifen use, and personal operative risks.
引用
- Matanes E, Volodarsky-Perel A, Eisenberg N, et al. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020. PMID: 33249269. doi:10.1016/j.jmig.2020.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。